Symbicort

AstraZeneca PLC
03 November 2004



ASTRAZENECA TO ADD RESULTS FROM ONGOING STUDIES IN RESUBMITTED SYMBICORT SINGLE
                          INHALER THERAPY FILE IN THE EU



AstraZeneca announced today that it has withdrawn its Symbicort Single Inhaler
Therapy file for the EU. As a result of discussions during the Mutual
Recognition Process, AstraZeneca expects a file to be submitted in the second
half of next year (2005), with additional data from recently completed (COSMOS)
and ongoing studies designed to provide further confirmation of this new
treatment concept.



Symbicort Single Inhaler Therapy is an innovative approach to the treatment of
asthma. AstraZeneca has already provided clear evidence that, when compared to
today's gold-standard treatments, it shows clinically significant benefits for
patients. Symbicort Single Inhaler Therapy yields a reduction of asthma
exacerbations, a reduced need for other treatments, a reduction in the number of
hospitalisations/emergency room visits and a decrease in overall corticosteroid
load. AstraZeneca firmly believes that this new treatment concept has a very
important role to play in the future management of asthma.



AstraZeneca is a major international healthcare business engaged in the
research, development, manufacture and marketing of prescription pharmaceuticals
and the supply of healthcare services. It is one of the world's leading
pharmaceutical companies with healthcare sales of over $18.8 billion and leading
positions in sales of gastrointestinal, oncology, cardiovascular, neuroscience
and respiratory products. AstraZeneca is listed in the Dow Jones Sustainability
Index (Global) as well as the FTSE4Good Index.



3 November 2004


Media Enquiries:
Edel McCaffrey, Tel: [phone]
Steve Brown, Tel: [phone]


Investor Relations:
Mina Blair, Tel: [phone]
Jonathan Hunt, Tel: [phone]



-Ends-


                      This information is provided by RNS
            The company news service from the London Stock Exchange